Prion diseases are fatal neurologic disorders caused by accumulation of a pathogenic isoform (PrP Sc ) of the prion protein (PrP). The recent discovery of the inhibitory action of quinacrine on PrP Sc formation in scrapie-infected neuroblastoma (ScN2a) cells raised the possibility of a treatment for patients with prion disease. To investigate the efficacy of quinacrine enantiomers, we measured the inhibitory effect of these isomers on PrP Sc formation in ScN2a cells. (S)-quinacrine exhibited superior antiprion activity compared with (R)-quinacrine and two generic quinacrines that appear to be racemates. Treatment with these various forms of quinacrine did not induce adverse changes affecting cell survival and the expression of marker proteins over a range of potentially therapeutic concentrations. Thus, quinacrine enantiomers demonstrated stereoselectivity on prion elimination but not cytotoxicity in ScN2a cells. Our results raise the possibility that in vivo treatment using one enantiomer of quinacrine may be superior to a racemic mixture, which is the form that is generally used when quinacrine is employed to treat parasitic diseases. (Lab Invest 2003, 83:837-843).
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SUMMARY: Prion diseases are fatal neurologic disorders caused by accumulation of a pathogenic isoform (PrP Sc ) of the prion protein (PrP). The recent discovery of the inhibitory action of quinacrine on PrP Sc formation in scrapie-infected neuroblastoma (ScN2a) cells raised the possibility of a treatment for patients with prion disease. To investigate the efficacy of quinacrine enantiomers, we measured the inhibitory effect of these isomers on PrP Sc formation in ScN2a cells. (S)-quinacrine exhibited superior antiprion activity compared with (R)-quinacrine and two generic quinacrines that appear to be racemates. Treatment with these various forms of quinacrine did not induce adverse changes affecting cell survival and the expression of marker proteins over a range of potentially therapeutic concentrations. Thus, quinacrine enantiomers demonstrated stereoselectivity on prion elimination but not cytotoxicity in ScN2a cells. Our results raise the possibility that in vivo treatment using one enantiomer of quinacrine may be superior to a racemic mixture, which is the form that is generally used when quinacrine is employed to treat parasitic diseases. (Lab Invest 2003, 83:837-843) . P rion diseases, including Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep, and bovine spongiform encephalopathy in cattle, are invariably fatal. Although many compounds have been reported to inhibit prion formation or enhance clearance in cultured cells as well as prolong incubation times in rodents, no compound has been found to reverse prion disease once clinical signs of CNS dysfunction have appeared (Caspi et al, 1998; Caughey and Race, 1992; Dickinson et al, 1975; Diringer and Ehlers, 1991; Ehlers and Diringer, 1984; Kimberlin and Walker, 1983; Peretz et al, 2001; Priola et al, 2000; Supattapone et al, 1999 Supattapone et al, , 2001 . Recently, one of us (SBP) as well as another independent group of investigators reported that both acridine and phenothiazine derivatives inhibit formation of the diseaseassociated pathogenic isoform (PrP Sc ) of the prion protein (PrP) in cultured scrapie-infected neuroblastoma (ScN2a) cells (Doh-ura et al, 2000; Korth et al, 2001) . In both studies, quinacrine inhibited PrP Sc accumulation in ScN2a cells with an effective concentration for half-maximal inhibition (EC 50 ) of 0.3 M. Exposure to quinacrine for 6 days eliminated PrP Sc in ScN2a cells permanently (Korth et al, 2001 ). Because quinacrine can penetrate the blood-brain barrier and a wealth of knowledge on the toxicity of quinacrine in humans has been established, these findings therefore prompted some of us to begin evaluating the efficacy of quinacrine in patients dying of CJD (B. Miller, M. Geschwind, S. J. DeArmond, and S. B. Prusiner, unpublished data). To date, our experience and that of others on the efficacy of quinacrine in the treatment of patients with prion disease have yielded mixed results.
Traditionally, the pharmacologic potency and selectivity of optical isomers against many diseases can differ enormously despite their identical physicochemical properties (Albert, 1960; Brocks and Jamali, 1995; Hutt and Tan, 1996) . There is considerable interest in switching from a racemate to a single enantiomeric isomer for many currently available drugs (Tucker, 2000) .
Quinacrine, first synthesized in the early 1930s, was extensively used as an antimalarial for nearly 2 decades. Because one of us (JCC) had previously studied the antimalarial activity of the two enantiomers, (S)-and (R)-quinacrine (Webster et al, 1991) , we explored the stereoselectivity of quinacrine on prion propagation. Because chronic administration of quinacrine is associated with side effects such as liver dysfunction, cardiomyopathy, and toxic psychosis (Findlay, 1951; Goodman and Gilman, 1955) , the use of one stereoisomer of quinacrine, if it was proven to be more efficacious than the racemic mixture, might be associated with diminished toxicity.
Here we report that (S)-quinacrine eliminates PrP Sc from ScN2a cells more effectively than either (R)-quinacrine or a racemic mixture, as demonstrated by Western blot analysis and ELISA results. Over a range of potentially therapeutic concentrations, (S)-and (R)-quinacrine neither produced cytotoxicity nor interfered with the expression of other proteins in cells. Although these in vitro results raise the possibility of (S)-quinacrine providing a more effective treatment against prion diseases, in vivo toxicologic, pharmacodynamic, and pharmacokinetic data from animal experiments are needed prior to any treatment in humans with a quinacrine enantiomer.
Results
To measure the antiprion effect of quinacrine enantiomers, we incubated ScN2a cells with generic quinacrine, (S)-quinacrine, or (R)-quinacrine ( Fig. 1) as described previously (Korth et al, 2001 ). On Western blot analysis, the 6-day incubation of ScN2a cells with 0.1 to 0.4 M (S)-quinacrine demonstrated a dosedependent reduction in the accumulation of proteaseresistant PrP Sc ( Fig. 2A , lanes 2-5). In contrast, a similar reduction in PrP Sc levels required 0.6 M of (R)-quinacrine ( Fig. 2A, lane 6 ). Incubation at concentrations Ͼ 0.6 M of (S)-quinacrine completely eliminated proteinase K (PK)-resistant PrP Sc ( Fig. 2A , lanes 6 -8), whereas more than 0.8 M of either (R)-quinacrine or generic quinacrine was needed to remove all PrP Sc ( Fig. 2A, lanes 7-8) . The pattern of PrP Sc disappearance in cell lysates incubated with (R)-quinacrine was similar to that of generic quinacrine used in earlier studies (Sigma Chemical, St. Louis, Missouri) ( Fig. 2A ). Densitometric analysis shows the PrP Sc elimination profiles of (S)-quinacrine, (R)-quinacrine, and generic quinacrine at various concentrations (Fig. 2B) .
In addition to densitometry, the antiprion activity of quinacrine enantiomers was quantified by ELISA measurements of the levels of PrP Sc in ScN2a cells (Fig. 3 ). Our ELISA results are similar to those obtained by Western blotting and its densitometric analysis (Fig. 2) . The efficiency of PrP Sc reduction by each enantiomer was almost identical at concentrations less than 0.2 M and greater than 0.8 M. However, at concentrations between 0.2 and 0.8 M, (S)-quinacrine was more efficient in reducing PrP Sc levels; at concentrations between 0.3 and 0.6 M, the antiprion activity of (S)-quinacrine was 2-to 6-fold greater than that of (R)-quinacrine.
We also compared the generic quinacrine (Panorama Compounding, Van Nuys, California) currently used for treating patients with prion disease (B. Miller, M. Geschwind, S.J. DeArmond, and S.B. Prusiner, unpublished data) to (S)-quinacrine. As expected, the generic quinacrine was less potent than (S)-quinacrine. At a concentration of 0.4 M, (S)-quinacrine removed almost all PrP Sc , whereas a concentration of 0.5 M of the generic quinacrine was required for the same effect (Fig. 4A ). Densitometric 
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analysis showed that the PrP Sc inhibition curve for the quinacrine used for treatment of patients with prion disease (Fig. 4B , open triangles) was similar but not identical to that of the quinacrine from Sigma Chemical (Fig. 2B, filled triangles) . In lower concentrations (0.1 to 0.3 M), the quinacrine used for treatment of patients was less effective at eliminating PrP Sc than the material from Sigma Chemical.
The effective concentrations for half-maximal inhibition (EC 50 ) of (R)-quinacrine, (S)-quinacrine, and generic quinacrine were calculated from densitometric analysis of Western blots and ELISA determinations. The EC 50 values for generic quinacrine obtained from Sigma and Panorama were 0.36 and 0.35 M, respectively, intermediate between those of (S)-and (R)-quinacrine. The EC 50 values of (S)-and (R)-quinacrine were 0.25 and 0.44 M, respectively, by Western blotting followed by densitometry (Fig. 2B) ; and 0.31 and 0.58 M, respectively, by ELISA (Fig. 3) . Our findings suggest that the generic quinacrine from Panorama is a mixture of quinacrine enantiomers that is similar to the generic quinacrine from Sigma.
To test whether various quinacrines used in this study caused alterations that affect cell survival, we conducted two independent assays in the ScN2a cells. Because both total protein and mitochondrial enzyme activity represent cell viability, we measured these changes in the ScN2a cells treated with various quinacrine concentrations for the studies described above. Total protein content in cells treated with quinacrine (racemic and enantiomeric) remained constant (Fig. 5A) . Total protein in individual culture dishes totaled 1.0 to 1.2 mg. In the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma) assay, cell viability is indicated by mitochondrial dehydrogenase activity, which is linearly proportional to the measured absorbance of formazan deposited in the living cells. Cells treated with either quinacrine enantiomer exhibited maximum viability at concentrations Ͻ 1.5 M (Fig. 5B) . The cytotoxicity of both enantiomers was almost equal at most concentrations, but (R)-quinacrine is less toxic between 1.8 and 2.0 M. Although such concentration ranges are beyond our interest, it is noteworthy that (R)-quinacrine demonstrated less cytotoxicity than (S)-quinacrine at 2.0 M; at concentrations Ͼ 2.5 M, both enantiomers were equally cytotoxic. The calculated LC 50 values (concentration causing half-maximal lethality) of (S)-and (R)-quinacrine were 1.98 and 2.24 M, respectively (Fig. 5B ), which were outside the range of concentrations needed to inhibit PrP Sc formation. In addition to the effects of quinacrine treatment on the survival of ScN2a cells, we also examined changes in tubulin and PrP C levels in the cells for alterations that may have been caused by quinacrine treatment. In cells treated with different concentrations of (S)-quinacrine, (R)-quinacrine, and generic quinacrine, rel- ative ratios indicated that tubulin and PrP C levels remained unchanged (Table 1) .
Discussion
In the studies described here, we investigated the antiprion activity and cytotoxicity of quinacrine enantiomers in ScN2a cells. We found that the (S)-quinacrine enantiomer showed greater potency in eliminating PrP Sc compared with that of (R)-quinacrine; the cytotoxicity of these two stereoisomers was similar. Whether our results with (S)-quinacrine offer a meaningful advance in the development of an effective treatment for prion diseases in humans and animals remains to be established.
It is unclear how the stereoselectivity of (S)-quinacrine against prions correlates with an earlier observation that only (R)-quinacrine was found in urine when a racemic mixture of quinacrine was administered to humans (Hammick and Chambers, 1945) . This finding implies that either a receptor binds (S)-quinacrine more readily or the pharmacokinetics of the enantiomers differ. In either case, excretion of (R)-quinacrine from the body might provide a clue to understanding the difference in antiprion activities of (S)-and (R)-quinacrine.
It is reasonable to ask whether (R)-quinacrine might be superior to (S)-quinacrine in treating prion disease if (R)-quinacrine is less toxic than (S)-quinacrine in vivo. In this scenario, inhibition of PrP
Sc formation by (R)-quinacrine would occur with fewer complications despite a higher dose of the drug. It will be important to develop an animal model of prion disease to address such questions in vivo. A recent report of experimental CJD in mice failed to show any prolongation of the incubation time following administration of a racemic mixture of quinacrine (Collins et al, 2002) .
Studies with racemic quinacrine demonstrated that concentrations in plasma increased rapidly and equilibrated between 30 and 100 g/L, depending on the doses, administration schedules, and species (Armored Medical Research Laboratory and Commission on Tropical Diseases, 1946; Dearborn, 1947; Shannon et al, 1944) . For eradication of malaria, concentrations of 30 to 50 g/L in plasma were sufficient, achievable by an oral dose of 100 mg three times daily for several days (Goodman and Gilman, 1955) . Quinacrine is absorbed rapidly, distributed widely, and removed slowly, accumulating in organs and tissues (Armored Medical Research Laboratory and Commission on Tropical Diseases, 1946; Shannon et al, 1944) . In vivo, the liver harbors one of the highest concentrations of quinacrine, whereas the brain retains one of the lowest concentrations (Army Malaria Research Unit, 1946; Dearborn et al, 1943) . Compared with levels in plasma, quinacrine concentrations can be up to 21,000 times greater in liver (Dearborn, 1947; Goodman and Gilman, 1955; Shannon et al, 1944 ) and 27.6 times greater in brain (Berliner et al, 1948) . From 0.5% to 3% of total quinacrine administered to animals was found in the brain (Army Malaria Research Unit, 1946; Blanchard and Schmidt, 1946; Dearborn et al, 1943) . Although the brain is one of the areas that exhibit the lowest levels of quinacrine concentration, uptake in brain tissue is significant; the deduced amount available in brain is comparable to the concentrations used to inhibit PrP Sc propagation completely in ScN2a cells. Quinacrine detected by fluorescence in brain sections of mouse and Guinea pig was distributed specifically in the cerebellum, cortex, hippocampus, and basal ganglia (Crowe and Burnstock, 1984; Howroyd and Gee, 1985) .
Both acute and chronic administration of large doses of quinacrine to rats resulted in extensive pathological lesions, including hepatic necrosis, fibrosis, and necrosis of the myocardium and voluntary muscles, and basophilic granules in several tissues (Fitzhugh et al, 1945; Siegel and Mushett, 1944) . When therapeutic doses for malaria were administered, with plasma quinacrine levels in excess of 100 g/L, 0.2% to 0.3% of cases developed toxic psychoses and one individual experienced an epileptiform seizure (Armored Medical Research Laboratory and Commission on Tropical Diseases, 1946; Goodman and Gilman, 1955) .
In conclusion, the development of animal models of prion disease in which oral quinacrine treatment can be administered will be important in determining whether or not the potent inhibition of PrP Sc demonstrated in ScN2a cultured cells can be extended into animals. Whether one stereoisomer of quinacrine will be found to be more potent in vivo, as is the case in cell culture, is unknown. Additionally, it is unclear whether one enantiomer is preferentially responsible for side effects such a liver toxicity, cardiomyopathy, and toxic psychosis. Although cell cultures provide a reasonable screening system for compounds that inhibit PrP Sc formation or enhance its clearance, it is crucial to identify compounds that can be administered long after prion infection has been established and produce a prolongation of the incubation time.
Materials and Methods

ScN2a Cell Culture and Quinacrine Treatment
Quinacrine enantiomers were synthesized individually. Synthesis and spectroscopic characterization of the enantiomers are described elsewhere . Generic quinacrine was obtained from Sigma Chemical and Panorama Compounding. The quinacrine was dissolved in phosphate buffered saline and stored at 4°C, with light protection during the treatment. A stock solution was prepared freshly every week.
ScN2a cells were cultivated in minimal essential medium with 10% FCS, 1% GlutaMax, and 1ϫ penicillin-streptomycin. For treatments, ScN2a cells were plated to 2% to 3% confluency. Various concentrations of generic quinacrine and the enantiomers were added to the cell cultures. Culture media including quinacrine were changed on alternate days during the 6-day treatment. Cells were washed with phosphate buffered saline twice and harvested in an equal volume of lysis buffer (20 mM Tris, pH 8.0; 150 mM NaCl, 0.5% NP40, 0.5% deoxycholate, sodium salt). The cell debris was removed by brief centrifugation, and cleared cell lysates were saved at Ϫ20°C until used.
PrP Sc Detection by Western Blot
After quantification of the cell lysates, an equal amount of cell lysates was subjected to PK digestion (20 g/ml) for 1 hour at 37°C. One hundred g of PK-digested cell lysates were centrifuged at 16,000 ϫ g for 1 hour then separated on a 12% Tris-Glycine SDS-PAGE gel and transferred onto a Protran BA-83 nitrocellulose membrane (Schleicher & Schuell, Keene, New Hampshire). The membrane was blocked by 5% nonfat milk. The chimeric human-mouse (HuM) D13 antibody and goat antihuman Fab conjugated to horseradish peroxidase were used as the primary and secondary antibodies, respectively, for the detection of PrP Sc . An enhanced chemiluminescent (Amersham Pharmacia, Piscataway, New Jersey) substrate for horseradish peroxidase was used for signal development. PrP Sc was quantified by densitometry using the Kodak 1D (Kodak, Rochester, New York) application.
PrP
Sc Detection by ELISA PK digestion of cell lysates and centrifugation conditions were the same as described above. The pellet was dissolved and denatured for 1 hour using 6 M guanidine thiocyanate. The denatured lysates were immobilized on the surface of a 96-well Immulon II ELISA plate (Dynex, Chantilly, Virginia) and the rest of the surface in the well was blocked by 3% BSA. Detection of PrP Sc was carried out by a 2-hour incubation of HuM-D18 antibody in 1ϫ Tris buffered saline followed by 1-hour incubation with goat antihuman Fab conjugated to alkaline phophatase (Pierce, Rockford, Illinois). An additional 1-hour incubation used 1-step pNPP (Pierce), an alkaline phosphatase substrate for the development of a colored product, which can be measured at 405 nm. The colorimetric intensity was measured by the microplate reader (Molecular Devices, Sunnyvale, California). A detailed description of this methodology will be described by Peretz et al, manuscript in preparation.
Measurement of Cell Viability
Cell viability was examined on two different levels: total protein contents and mitochondrial activity. Total protein contents was obtained by multiplication of the volume and the concentration of lysate quantified using a bicinchoninic acid protein quantification kit (Pierce). Mitochondrial activity was measured by the MTT assay. After treatment with quinacrine, the cells were further incubated in fresh media with a final concentration of 0.5 mg/ml MTT for 3 hours. The insoluble substrates converted by the active mitochondrial dehydrogenases in the surviving cells were released by addition of acidic alcohol (0.05 N HClisopropanol) and measured at 570 nm.
Measurement of Tubulin and PrP C Content
Tubulin and PrP C in quinacrine-treated cells were measured by Western blotting followed by densitometry. An equal volume (20 l) of the harvested lysate was separated in an SDS-PAGE gel and transferred to a nitrocellulose membrane. Anti-␣-tubulin (Zymed, South San Francisco, California) and HuM-D13 antibodies were used for detection for tubulin and PrP C , respectively. Other conditions and procedures were as described above.
